OptiNose, Inc. (OPTN)

Market Cap	92.87M
Revenue (ttm)	78.23M
Net Income (ttm)	-21.54M
Shares Out	10.13M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,658
Open	9.21
Previous Close	9.16
Day's Range	9.16 - 9.23
52-Week Range	4.82 - 20.03
Beta	-0.88
Analysts	Hold
Price Target	9.00 (-1.85%)
Earnings Date	May 13, 2025

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Oct 13, 2017
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: OPTN
• Website: https://www.optinose.com

Financial Performance

In 2024, OptiNose's revenue was $78.23 million, an increase of 10.20% compared to the previous year's $70.99 million. Losses were -$21.54 million, -39.29% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for OPTN stock is "Hold." The 12-month stock price forecast is $9.0, which is a decrease of -1.85% from the latest price.

Price Target

$9.0

(-1.85% downside)

Analyst Consensus: Hold